Allogene Therapeutics Ownership | Who Owns Allogene Therapeutics?
Allogene Therapeutics Ownership Summary
Allogene Therapeutics is owned by 37.37% institutional investors, 11.06% insiders, and 51.58% retail investors. Pfizer is the largest institutional shareholder, holding 9.99% of ALLO shares. American Funds SMALLCAP World A is the top mutual fund, with 5.10% of its assets in Allogene Therapeutics shares.
ALLO Ownership Benchmark
| Type | Name | % Inst | % Insiders | % Retail |
|---|---|---|---|---|
| Stock | Allogene Therapeutics | 37.37% | 11.06% | 51.58% |
| Sector | Healthcare Stocks | 35.58% | 11.87% | 52.55% |
| Industry | Biotech Stocks | 35.75% | 11.83% | 52.41% |
Institutional Shareholders
Top Institutional Shareholders by Total Shares
| Holder | Shares | % Holding | Value |
|---|---|---|---|
| Pfizer | 22.03M | 9.99% | $49.79M |
| Blackrock | 16.45M | 9.72% | $38.32M |
| Blackrock funding, inc. /de | 19.09M | 8.65% | $46.58M |
| Tpg gp a | 18.72M | 8.48% | $45.67M |
| Vanguard group | 9.25M | 4.17% | $12.67M |
| State street | 8.66M | 3.93% | $21.13M |
| Primecap management co/ca/ | 8.38M | 3.80% | $20.45M |
| Citadel advisors | 6.79M | 3.08% | $16.58M |
| Price t rowe associates inc /md/ | 5.38M | 2.44% | $13.13M |
| Two sigma investments, lp | 5.38M | 2.44% | $13.12M |
Top Institutional Shareholders by % of Total Assets
| Holder | Shares | % Assets | Value |
|---|---|---|---|
| Pfizer | 22.03M | 20.85% | $49.79M |
| Vida ventures advisors | 1.80M | 7.59% | $2.23M |
| Wildcat capital management | 2.92M | 6.71% | $7.13M |
| Patient square capital lp | 3.45M | 1.49% | $8.42M |
| Tpg gp a | 18.72M | 1.24% | $45.67M |
| Boxer capital management | 2.73M | 0.87% | $6.65M |
| Dafna capital management | 1.37M | 0.76% | $3.34M |
| Bioimpact capital | 2.24M | 0.42% | $5.47M |
| Harold davidson & associates | 289.22K | 0.34% | $705.70K |
| Frazier life sciences management | 3.80M | 0.24% | $9.26M |
Top Buyers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Blackrock | 16.45M | 0.00% | 6.79M |
| State street | 8.66M | 0.00% | 5.90M |
| Marshall wace, llp | 3.45M | 0.01% | 3.16M |
| Boxer capital management | 2.73M | 0.87% | 2.73M |
| Bioimpact capital | 2.24M | 0.42% | 2.24M |
Top Sellers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Capital world investors | - | - | -11.15M |
| Lynx1 capital management lp | 546.12K | 0.14% | -10.51M |
| Darwin global management | - | - | -10.48M |
| Citadel advisors | 6.79M | 0.00% | -5.32M |
| Boxer capital | - | - | -3.85M |
New Positions
| Holder | Shares | % Assets | Change | Value |
|---|---|---|---|---|
| Boxer capital management | 2.73M | 0.87% | 2.73M | $6.65M |
| Bioimpact capital | 2.24M | 0.42% | 2.24M | $5.47M |
| Jacobs levy equity management | 2.01M | 0.02% | 2.01M | $4.91M |
| Balyasny asset management | 1.18M | 0.00% | 1.18M | $2.89M |
| Vanguard fiduciary trust | 1.09M | 0.00% | 1.09M | $2.66M |
Sold Out
| Holder | Change |
|---|---|
| Capital performance advisors llp | -41.00 |
| Raymond james financial | -45.00 |
| Dunhill financial | -70.00 |
| Federation des caisses desjardins du quebec | -100.00 |
| Private wealth management group | -140.00 |
Institutional Ownership Trends
| Date | Holdings | Change % | Shares | Change % | Ownership | Change % | Increased Position | Change % | Decreased Position | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| Mar 31, 2026 | 119 | -32.00% | 82,438,846 | -49.31% | 37 | 0.70% | 68 | -16.05% | 22 | -51.11% |
| Dec 31, 2025 | 108 | -37.93% | 99,292,779 | -38.89% | 44 | 0.81% | 46 | -51.06% | 31 | -16.22% |
| Sep 30, 2025 | 166 | 8.50% | 162,395,329 | -2.90% | 74 | 1.27% | 85 | 26.87% | 37 | -11.90% |
| Jun 30, 2025 | 160 | -6.98% | 183,929,908 | -6.69% | 84 | 1.00% | 66 | -27.47% | 47 | 14.63% |
| Mar 31, 2025 | 170 | -1.73% | 196,870,758 | 4.48% | 91 | 1.13% | 90 | -2.17% | 41 | - |
Top Mutual Funds Shareholders
| Holder | Shares | % Holding | Change |
|---|---|---|---|
| American Funds SMALLCAP World A | 11.15M | 5.10% | -1.12M |
| Vanguard Total Stock Mkt Idx Inv | 8.43M | 2.44% | 3.55M |
| Fidelity Growth Compy Commingled Pl O | 4.58M | 2.19% | - |
| Vanguard US Total Market Shares ETF | 4.34M | 2.00% | - |
| Fidelity Select Health Care | 4.00M | 1.88% | -350.00K |
| SPDR® S&P Biotech ETF | 3.90M | 1.84% | -23.78K |
| State Street® SPDR® S&P® Biotech ETF | 5.93M | 1.72% | -58.50K |
| Fidelity Series Small Cap Opps | 3.54M | 1.69% | -141.30K |
| T. Rowe Price Health Sciences | 3.83M | 1.67% | 1.85M |
| Vanguard Capital Opportunity Inv | 5.36M | 1.56% | 175.00K |
Recent Insider Transactions
| Date | Name | Role | Activity | Value |
|---|---|---|---|---|
| Apr 21, 2026 | Yoshiyama Annie | SVP, Finance | Sell | $22.14K |
| Mar 31, 2026 | Beneski Benjamin Machinas | SVP, Chief Technical Officer | Sell | $7.17K |
| Mar 16, 2026 | Beneski Benjamin Machinas | SVP, Chief Technical Officer | Sell | $11.94K |
| Mar 16, 2026 | Chang David D | President and CEO | Sell | $117.97K |
| Mar 02, 2026 | Beneski Benjamin Machinas | SVP, Chief Technical Officer | Sell | $18.54K |
Insider Transactions Trends
| Date | Buy | Sell |
|---|---|---|
| 2026 Q2 | - | 1 |
| 2026 Q1 | - | 11 |
| 2025 Q4 | - | 2 |
| 2025 Q2 | - | 2 |
| 2025 Q1 | - | 9 |
ALLO Ownership FAQ
Try Tickergate Pro Free
Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)
Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis
Discover trending investment themes
Find your next best investment
Research stocks using tools